A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma
Colección de datos
Enfermedades de la Mama+2
+ Neoplasias de la Mama
+ Neoplasias
Estudio de Tratamiento
Resumen
Fecha de inicio: 1 de octubre de 2005
Fecha en la que se inscribió al primer participante.This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.
Protocolo
Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.Se reclutarán 15 pacientes
Número total de participantes que el ensayo clínico espera reclutar.Estudio de Tratamiento
Elegibilidad
Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.Mujer
Sexo biológico de los participantes elegibles para inscribirse.De 18 a 85 años
Rango de edades de los participantes que pueden unirse al estudio.Voluntarios sanos no permitidos
Indica si personas sanas, sin la condición que se estudia, pueden participar.Condiciones
Patología
Criterios
Inclusion Criteria: * Biopsy confirmed recurrent soft tissue breast carcinoma * At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter * Performance Status: Karnofsky 70-100% or ECOG 0-2 * Life Expectancy: At least 6 months * Hematopoietic: * White blood cell count (WBC) at least 3000/mm3 * Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3) * Hemoglobin at least 10 g/dL * Platelet count at least 100,000/mm3 * Coagulopathy: International Normalized Ratio (INR) at least 1.5. * Renal Function: Creatinine = 0.05-0.11 mmol/L * Hepatic Function: * Bilirubin = 3-21 umol/L * AST/ALT ≤ 3 times the upper limit of normal (ULN) * Cardiovascular Function: No major cardiovascular disease * Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits * Immunological Function: Adequate immune system function in the opinion of the investigator Exclusion Criteria: * Radiation therapy to study lesions within 4 weeks * Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin) * Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks * Investigational agents within 4 weeks (or 5 half-lives) * Anti-tumor vaccine therapy within 12 weeks * Concurrent illness: * Severe diabetes or extremity complications due to diabetes * Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results * Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis * Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating * Known or suspected brain metastases or spinal cord compression.
Plan de Estudio
Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.Objetivos del Estudio
Objetivos Primarios
Objetivos Secundarios
Centros del Estudio
Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.Este estudio tiene una ubicación